Loading market dashboard
Vanguard Industrials ETF
VISFinancial ServicesAMEXUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Taiwan Semiconductor Manufacturing Company said on Friday that it is planning to sell up to 152 million shares in Vanguard International Semiconductor through a block trade to institutional investors. The company said the divestment is aimed at sharpening focus on its core operations while maintaining strategic cooperation with VIS in areas including interposer production and gallium nitride technology licensing.
Eagle Wealth Advisors LLC acquired a new stake in shares of Vanguard Industrials ETF (NYSEARCA:VIS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,882 shares of the company's stock, valued at approximately $860,000. Vanguard Industrials ETF accounts for
Edmonton, Alberta--(Newsfile Corp. - April 15, 2026) - Visionstate Corp. (TSXV: VIS) today announced the addition of a new Ontario-based health region to its compliance software platform, representing five hospitals and associated facilities, while also reporting continued expansion of its footprint in the United States through additional deployments within Class A office tower environments in New York City. These developments build on the Company's previously reported subscription growth and reflect continued adoption of its compliance platform across multiple sectors.
Launched on September 23, 2004, the Vanguard Industrials Index Fund ETF Shares (VIS) is a passively managed exchange traded fund designed to provide a broad exposure to the Industrials - Broad segment of the equity market.
Calder Financial LLC purchased a new stake in Vanguard Industrials ETF (NYSEARCA:VIS) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,740 shares of the company's stock, valued at approximately $2,011,000. Vanguard Industrials ETF accounts for about 2.0%
Sometimes, the least likely group ends up doing the best. But investors won't know for sure until the year is complete.
Vanguard Industrials ETF receives a "Buy" rating, supported by robust technicals and sector resilience amid geopolitical developments. VIS trades at a premium 26x P/E and 2.3x PEG, but sector diversification and exposure to AI and Aerospace & Defense offset valuation concerns. VIS's portfolio is well-diversified, with no single holding above 5.1% and top 10 assets comprising only 30%.
Capital Management Associates Inc increased its stake in Vanguard Industrials ETF (NYSEARCA:VIS) by 76.8% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,050 shares of the company's stock after acquiring an additional 2,629 shares during
JPMorgan Chase and Co. raised its stake in shares of Vanguard Industrials ETF (NYSEARCA:VIS) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,334 shares of the company's stock after purchasing an additional 2,506 shares during the quarter. JPMorgan
Bank of America Corp DE grew its holdings in Vanguard Industrials ETF (NYSEARCA:VIS) by 6.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,915,208 shares of the company's stock after acquiring an additional 247,479 shares during the quarter. Bank
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript
ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, and its subsidiary, Visara, Inc. (Visara), today announced positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Topline results show that VIS-101 produced rapid, robust and durable treatment responses in wet AMD, with potential best-in-class durability and a favorable safety profile. Wet AMD affects more than 20 million people globally1.
